What is GLP1 injection "Saxenda"?
Saxenda is a drug called a GLP1 receptor agonist, which is an injectable drug that blocks the hormone GLP1. GLP1 is a hormone that is naturally secreted in the human body and promotes insulin secretion in response to rising blood sugar levels, thereby lowering blood sugar levels.
After being approved by the US FDA as a diabetes treatment in 2010, its weight loss effects drew attention and it was approved by the US FDA as an obesity treatment in 2014. It was also approved in Europe (EMA) the following year in 2015, and was approved by the Ministry of Health, Labor and Welfare in Japan as an obesity treatment in 2020. It is currently widely used to treat obesity and improve lifestyle-related diseases.
.png){kind=small}
Active ingredient: Liraglutide
Liraglutide is a GLP-1 receptor agonist whose active ingredient acts on GLP-1 (glucagon-like peptide-1).
Mechanism of action
.png){kind=small}
.png){kind=small}
.png){kind=small}
appetite suppression
It acts on the brain's satiety center (hypothalamus) and suppresses appetite.
Blood sugar control
- Promotes the secretion of insulin (a hormone that lowers blood sugar levels) and suppresses the rise in blood sugar after meals.
- It suppresses the secretion of glucagon (a hormone that raises blood sugar levels), reduces sugar release from the liver , and stabilizes blood sugar levels.
Suppresses stomach motility
By slowing down the rate at which food moves from the stomach to the intestines, food stays in the stomach for longer, making you feel fuller for longer.
As a result, you will lose weight and become less prone to gaining weight.
* Unapproved drugs, etc.
Saxenda is an unapproved drug in Japan that has not been approved under the Pharmaceuticals and Medical Devices Act.
※ How to obtain
The Saxenda used in our hospital is manufactured by Novo Nordisk Pharma and is personally imported from overseas.
* Availability of approved drugs in Japan
There are no drugs approved for use in Japan.
* Information regarding safety in other countries
It is an appetite suppressant that has been approved by the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) for the treatment of obesity.
For more information about Saxenda, please visit https://www.saxenda.com/ .
投薬に関して
Please note that for Japanese people, there is no scientific evidence for taking Saxenda at 2.4mg to 3.0mg, so you do so at your own risk.
Please inject once a day . You can inject it at any time. It is not related to meals, so you can inject it before breakfast.
There is no problem if you don't take it.
.png){kind=small}
Timing of increase
上記のルールで投与量の調整をしてください。
少食が続くようなら、無理に１週間ごとに増量せずともかまいません。
※食欲が抑えられたと感じた量で継続して下さい。必ずしも最大量3.0mgまで増量し なくてもかまいません。
悪心を感じたら、減量もしくは、その時の量で継続して下さい。無理に増量しないでください。
Saxenda side effects
Side effects are most prevalent only in the early stages
Side effects are mild, but will subside over time. Since it is dose-dependent, start with a small dose and increase the dose as you progress.
If you do, it won't impair your quality of life.
The most common side effect is gastrointestinal upset
It slows gastric emptying, causing mainly nausea and heartburn, with only a few cases of constipation, diarrhea, or vomiting.
The following is a list of side effects that occurred with a frequency of 2% or more when the drug was approved overseas.
